Evidence map›Paper›PMID 42800840›Full record

ArticleEMBO reports2026

The role of autoproteolysis and mitoribosomal proteins in the regulation of the mitochondrial LACTB tumor suppressor.

Sara Escudeiro-Lopes, Juan M Gonzalez-Morena, Alzbeta Baudysova, Michal Svoboda, Pavel Marasek, Gabriel Rodriguez-Gomez, Jessica Ferreira Mendes, Chung Weng Phang, Sravan Kumar Miryala, Pavel Jakoube and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sara Escudeiro-LopesInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-1542-7408
Juan M Gonzalez-MorenaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0003-2932-0756
Alzbeta BaudysovaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Michal SvobodaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Pavel MarasekInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Gabriel Rodriguez-GomezInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Jessica Ferreira MendesInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Chung Weng PhangInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0003-4619-8895
Sravan Kumar MiryalaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0001-7643-5033
Pavel JakoubeInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-5422-4136
Beata KovarovaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
Susana MachadoInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-3152-1701
Yuxiong FengZhejiang Provincial Key Laboratory of Pancreatic Disease, First Affiliated Hospital, and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Zuzana KeckesovaInstitute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic. keckesova@uochb.cas.cz.ORCID http://orcid.org/0000-0003-3374-6266

Funding

EMBO Installation Grant 2018Granting Agency of Czech Republic 18-24473YMinistry of Educatin, Youth and Sports of the Czech Republic, and European Social Fund CZ.02.2.69/0.0/0.0/19_074/0016322Ministry of Science and Technology of the People's Republic of China (MOST) 2020YFA0803300National natural Science Foundation of China 32270783Programme Exceles LX22NPO5102
6 · The paper itself

Abstract

Tumor suppressors represent one of the first lines of defense against malignant transformation, and their inactivation in cells leads to the onset of tumorigenesis. Cancer cells employ various mechanisms to inactivate cellular tumor suppressors, including epigenetic silencing and mutagenesis. Less understood are the mechanisms by which cancer cells inactivate tumor suppressors post-translationally. Here, we uncovered a previously undescribed post-translational mechanism by which cancer cells inactivate the potent mitochondrial tumor suppressor LACTB in breast cancers. We discovered that the substrate of LACTB can be LACTB itself; LACTB possesses autoproteolytic activity, which is important for modulating its tumor suppressor activity. We demonstrate that cancer cells exploit this feature of LACTB to induce LACTB's self-degradation. This is mechanistically realized through upregulation of mitochondrial MRPS34 protein, which, through interaction with LACTB, is a positive regulator of LACTB's autoproteolytic activity and a negative regulator of LACTB. This study provides insights into how cancer cells fine-tune the expression and activity of tumor suppressors to promote tumorigenesis.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.